FDA advisers to review COVID-19 shots for young kids, boosters this month
Reuters
Published Oct 01, 2021 02:35PM ET
Updated Oct 01, 2021 03:28PM ET
(Reuters) - An advisory panel of experts to the U.S. drug regulator will hold meetings this month to review data on Pfizer Inc (NYSE:PFE)'s COVID-19 vaccine in young children, and whether to clear booster doses of Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ)'s vaccines.
The U.S. Food and Drug Administration's announcement on Friday comes as health authorities seek to mitigate a potential surge of cases this fall, with schools already open nationwide.
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) panel will hold a meeting on Oct. 14 to discuss a booster dose of Moderna vaccine, and Johnson & Johnson on Oct. 15.
VRBPAC will discuss authorizing Pfizer Inc's COVID-19 vaccine for children aged five through 11 on Oct. 26, the FDA said.
Last month, the agency authorized a booster dose of the Pfizer and BioNTech vaccine for older adults and some Americans at high-risk of illness.
About 4 million Americans had received a booster dose as of Thursday, according to data from the Centers for Disease Control and Prevention.
The panel will also review data on receiving a booster dose of a different vaccine than the one used in the original vaccine series, called "mix and match" boosters.
Reuters reported in June that infectious disease experts were weighing the need for booster shots of the Pfizer/BioNTech or Moderna's mRNA-based vaccines for Americans who received the J&J one-dose vaccine due to the prevalence of the Delta variant of the coronavirus.
Separately, the FDA does not plan to extend the shelf life of hundreds of thousands of J&J vaccine doses beyond the current recommendation of six months from the manufacturer, NBC News, citing an internal email.
The FDA and J&J did not immediately respond to Reuters' request for comment.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.